-transparent.png){kind=logo}
The pharmacological characteristics of the presynaptic 5-HT receptor associated with the modulation of 5-HT release were investigated in a preparation of rat spinal cord synaptosomes (nerve terminals) superfused with a Tris-buffered Krebs solution containing fluoxetine (1 microM). The 5-HT receptor agonists serotonin (1-100 nM), lysergic acid diethylamide (10 nM-1 microM) and the 5-HT1B receptor agonists 1-(m-trifluoromethylphenyl)piperazine (100 nM-1 microM) and 1-(m-chlorophenyl) piperazine (100 nM-3 microM) concentration dependently decreased [3H]5-HT release, while 8-hydroxy-2-(di-n-propylamino)tetralin, a selective 5-HT1A receptor agonist, was inactive. The actions of the effective agonists were reversed by quipazine, an antagonist with high affinity for 5-HT1B binding sites, but not by spiperone, a 5-HT1A receptor antagonist. Furthermore, mesulergine, a 5-HT1C receptor antagonist was ineffective in reversing the action of 5-HT on [3H]5-HT release. These data indicate that the rat spinal cord nerve terminal autoreceptor has characteristics similar to the 5-HT1B binding site.
L Brown, and
J Amedro, and
G Williams, and
D Smith
January 1988,
Neuropharmacology,
L Brown, and
J Amedro, and
G Williams, and
D Smith
July 2007,
Brain research,
L Brown, and
J Amedro, and
G Williams, and
D Smith
August 1987,
Neuropharmacology,
L Brown, and
J Amedro, and
G Williams, and
D Smith
December 1986,
Naunyn-Schmiedeberg's archives of pharmacology,
L Brown, and
J Amedro, and
G Williams, and
D Smith
November 1981,
European journal of pharmacology,
L Brown, and
J Amedro, and
G Williams, and
D Smith
January 2015,
PloS one,
L Brown, and
J Amedro, and
G Williams, and
D Smith
December 2012,
Synapse (New York, N.Y.),
L Brown, and
J Amedro, and
G Williams, and
D Smith
March 1999,
General pharmacology,
L Brown, and
J Amedro, and
G Williams, and
D Smith
September 2009,
Archives of orthopaedic and trauma surgery,
L Brown, and
J Amedro, and
G Williams, and
D Smith
April 2010,
Experimental neurology,
